Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

July 25, 2024

Study Completion Date

August 7, 2024

Conditions
Schizophrenia
Interventions
DRUG

Lumateperone 42 mg

Lumateperone 42 mg capsules administered orally, once daily.

DRUG

Placebo

Matching capsules administered orally, once daily.

Trial Locations (43)

1282

Clinical Site, Novi Iskar

1377

Clinical Site, Sofia

3000

Clinical Site, Vratsa

4002

Clinical Site, Plovdiv

5000

Clinical Site, Veliko Tarnovo

5047

Clinical Site, Tserova Koria

5500

Clinical Site, Lovech

5800

Clinical Site, Pleven

6100

Clinical Site, Kazanlak

6600

Clinical Site, Kardzhali

7003

Clinical Site, Rousse

7700

Clinical Site, Targovishte

8000

Clinical Site, Burgas

9747

Clinical Site, Tsarev Brod

11000

Clinical site, Belgrade

23330

Clinical Site, Novi Kneževac

26220

Clinical Site, Kovin

30331

Clinical Site, Atlanta

33016

Clinical Site, Miami Lakes

33021

Clinical Site, Hollywood

33334

Clinical Site, Oakland Park

34000

Clinical Site, Kragujevac

44720

Clinical Site, North Canton

60640

Clinical Site, Chicago

63141

Clinical Site, St Louis

72211

Clinical Site, Little Rock

75080

Clinical Site, Richardson

75115

Clinical Site, DeSoto

78754

Clinical Site, Austin

89102

Clinical Site, Las Vegas

90230

Clinical Site, Culver City

90703

Clinical Site, Cerritos

91763

Clinical Site, Montclair

91945

Clinical Site, Lemon Grove

92845

Clinical Site, Garden Grove

92869

Clinical Site, Orange

95080

Clinical Site, Tuszyn

907006

Clinical Site, Bellflower

02114

Clinical Site, Boston

08009

Clinical Site, Berlin

80-214

Clinical Site, Gdansk

80-282

Clinical Site, Gdansk

3-8300

Clinical Site, Gorlice

Sponsors
All Listed Sponsors
lead

Intra-Cellular Therapies, Inc.

INDUSTRY